Oncotype Dx Score And Radiation Therapy

Genomic health oncotype oncotype dx recurrence score dcis score and pass it on. Tailorx trial demonstrated the precision with which the oncotype dx breast recurrence score test allows us to predict with confidence the patients who will benefit from chemotherapy and who will not.

Predictive Value Of Oncotypedx Ductal Carcinoma In Situ Score
www.researchgate.net

Until every woman knows are registered trademarks and put breast cancer to the test and put chemo to the test are pending registered trademarks of genomic health inc.

Oncotype dx score and radiation therapy. Find out if your patient is eligible and order the test. It looks at the unique biology of a patients tumorso you can better personalize the treatment plan for each patients unique situation. As the oncotype dcis scores were validated using patients who did not receive radiation therapy it is unclear whether and how the scores should be used for including or forgoing radiation therapy.

Your treatment plan may include radiation therapy hormonal therapy both or neither. The oncotype dx breast dcis score test is the first clinically validated commercially available genomic test for patients with dcis. Webmd explains how the oncotype dx test helps doctors predict if breast cancer will return and assists in determining the proper cancer treatment.

Knowing the oncotype dx breast recurrence score can guide you and your patient to the right systemic adjuvant treatment decision. If youre deciding on treatments after dcis surgery you might want to ask your doctor if the oncotype dx dcis test might help figure out if you would benefit from radiation therapy. The oncotype dx dcis test was a critical piece of data that helped keep me moving forward in my own process.

Being given personalized information specific to my tumor allowed me to move ahead confidently for me the oncotype dx dcis test was a key piece of evidence which confirmed my decision to have a double mastectomy. The oncotype dx dcis score is a multigene assay which allows for the addition of molecular information to traditional clinical and pathologic factors to help guide treatment decisions. Studies have shown that oncotype dx is useful for both purposes.

Here we present two case examples illustrating the use of the oncotype dcis score in clinical practice. A detailed breast recurrence score report is generated for each patient. So the oncotype dx test is both a prognostic test since it provides more information about how likely or unlikely the breast cancer is to come back and a predictive test since it predicts the likelihood of benefit from chemotherapy or radiation therapy treatment.

Genomic health makes understanding oncotype dx breast recurrence score test results as easy as possible. The report contains the recurrence score resulta number between 0 100that assesses the 9 year risk of distant recurrence 1 in node negative patients 5 year distant recurrence or mortality in node positive 3.

Interpreting Results Oncotype Dx Colon Recurrence Score
www.oncotypeiq.com